阿司匹林:药理学和临床应用。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2011-11-17 DOI:10.1155/2012/173124
Enma V Paez Espinosa, John P Murad, Fadi T Khasawneh
{"title":"阿司匹林:药理学和临床应用。","authors":"Enma V Paez Espinosa,&nbsp;John P Murad,&nbsp;Fadi T Khasawneh","doi":"10.1155/2012/173124","DOIUrl":null,"url":null,"abstract":"<p><p>Antiplatelet therapy has been documented to reduce risks of cardiovascular disease after acute myocardial infarction, coronary artery bypass graft, and in chronic atrial fibrillation patients, amongst other risk factors. Conventional management of thrombosis-based disorders includes the use of heparin, oral anticoagulants, and the preferred antiplatelet agent aspirin. Interestingly, aspirin was not intended to be used as an antiplatelet agent; rather, after being repurposed, it has become one of the most widely prescribed antithrombotic drugs. To this end, there have been several milestones in the development of antiplatelet agents in the last few decades, such as adenosine diphosphate receptor inhibitors, phosphodiesterase inhibitors, and GPIIb/IIIa inhibitors. However, given some of the limitations of these therapies, aspirin continues to play a major role in the management of thrombotic and cardiovascular disorders and is expected to do so for years to come.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"173124"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/173124","citationCount":"59","resultStr":"{\"title\":\"Aspirin: pharmacology and clinical applications.\",\"authors\":\"Enma V Paez Espinosa,&nbsp;John P Murad,&nbsp;Fadi T Khasawneh\",\"doi\":\"10.1155/2012/173124\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Antiplatelet therapy has been documented to reduce risks of cardiovascular disease after acute myocardial infarction, coronary artery bypass graft, and in chronic atrial fibrillation patients, amongst other risk factors. Conventional management of thrombosis-based disorders includes the use of heparin, oral anticoagulants, and the preferred antiplatelet agent aspirin. Interestingly, aspirin was not intended to be used as an antiplatelet agent; rather, after being repurposed, it has become one of the most widely prescribed antithrombotic drugs. To this end, there have been several milestones in the development of antiplatelet agents in the last few decades, such as adenosine diphosphate receptor inhibitors, phosphodiesterase inhibitors, and GPIIb/IIIa inhibitors. However, given some of the limitations of these therapies, aspirin continues to play a major role in the management of thrombotic and cardiovascular disorders and is expected to do so for years to come.</p>\",\"PeriodicalId\":75222,\"journal\":{\"name\":\"Thrombosis\",\"volume\":\"2012 \",\"pages\":\"173124\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2012/173124\",\"citationCount\":\"59\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thrombosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2012/173124\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2011/11/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2012/173124","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/11/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 59

摘要

在其他危险因素中,抗血小板治疗已被证明可以降低急性心肌梗死、冠状动脉搭桥术和慢性心房颤动患者后心血管疾病的风险。血栓形成性疾病的常规治疗包括使用肝素、口服抗凝剂和首选抗血小板药物阿司匹林。有趣的是,阿司匹林并不打算用作抗血小板药物;相反,经过重新利用,它已经成为最广泛使用的抗血栓药物之一。为此,在过去的几十年里,抗血小板药物的发展有几个里程碑式的进展,如二磷酸腺苷受体抑制剂、磷酸二酯酶抑制剂和GPIIb/IIIa抑制剂。然而,鉴于这些疗法的一些局限性,阿司匹林继续在血栓性和心血管疾病的治疗中发挥主要作用,并有望在未来几年发挥作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Aspirin: pharmacology and clinical applications.

Antiplatelet therapy has been documented to reduce risks of cardiovascular disease after acute myocardial infarction, coronary artery bypass graft, and in chronic atrial fibrillation patients, amongst other risk factors. Conventional management of thrombosis-based disorders includes the use of heparin, oral anticoagulants, and the preferred antiplatelet agent aspirin. Interestingly, aspirin was not intended to be used as an antiplatelet agent; rather, after being repurposed, it has become one of the most widely prescribed antithrombotic drugs. To this end, there have been several milestones in the development of antiplatelet agents in the last few decades, such as adenosine diphosphate receptor inhibitors, phosphodiesterase inhibitors, and GPIIb/IIIa inhibitors. However, given some of the limitations of these therapies, aspirin continues to play a major role in the management of thrombotic and cardiovascular disorders and is expected to do so for years to come.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信